Advanced searches left 3/3

Multiple Myeloma - Europe PMC

Summarized by Plex Scholar
Last Updated: 13 May 2022

* If you want to update the article please login/register

Identification of key genes and miRNA-mRNA regulatory networks associated with bone marrow immune microenvironment regulations in multiple myeloma by integrative bioinformatics analysis.

Multiple myeloma has been linked to the deregulation of microRNAs and genes in the bone marrow microenvironment, which may have been responsible for multiple myeloma formation. In addition, we found 9 upregulated hub genes and 52 downregulated hub genes in MM that is also targeted by DEmiRs. The expression of DEmiRs in two hub genes is linked to MM patient survival prognosis. In the TME of MM, the expression of CDKN2A is linked to immune signatures, including CD4+ regulatory T cells, T cell exhaustion, MHC Class I, immune checkpoint genes, macrophages, neutrophils, and TH2 cells. In the MM's independent cohorts, we revealed the consistently deregulated expression level of key gene CDKN2A and its co-regulatory DEmiRs, including hsa-mir-192, hsa-mir-10b, hsa-mir-492, and hsa-mir-24. Identifying key genes and miRNA-mRNA regulatory networks may provide new molecular insight into the tumor immune microenvironment in MM.

Source link: https://europepmc.org/article/MED/35536760


Promising therapeutic approaches for relapsed/refractory multiple myeloma.

Objectitive MM treatment protocols are particularly difficult. By reviewing the most recent clinical trials and emerging technologies in drug discovery, we'll highlight the most recent findings and emerging trends in the field of RRMM therapy. In Table, the main findings of the most recent clinical trial were summarized. Results In the final analysis involving anti-BCMA CAR T-cell therapy, combined CAR T-cell therapy, antibody-drug conjugates, bispecific Absorption, and CELMoDs, a total of 13 studies were included. In the final report involving anti-BCMA CAR T-cell therapy, Combined CAR T-cell therapy, combined CAR T-cell therapy, antibody-drug conjugates, CELMoDs, The main therapeutic efficacy and side effects of medications were outlined. MM patients with relapsed/refractory multiple myeloma are given more options for relapsed/refractory multiple myeloma. Patients' appropriate therapy should be tailored to disease-related conditions, such as previous treatments, duration of exposure to previous medications, laboratory and biochemical characteristics of relapse, and the relationship of patient comorbidities with known AE profiles of the various drugs.

Source link: https://europepmc.org/article/MED/35287555


False positive results: a challenge for laboratory physicians and hematologists in treating multiple myeloma with daratumumab.

In 2019, China approved Daratumumab injection for the treatment of acute or refractory multiple myeloma. However, the molecular weight of daratumab, an immunoglobin G1 kappa human monoclonal antibody, was similar to that of M protein, and could not be distinguished from IgG M protein in SPEP and SIFE, but not distinguishable from IgG M protein.

Source link: https://europepmc.org/article/MED/35255237


Identification of biomarkers for early diagnosis of multiple myeloma by weighted gene co-expression network analysis and their clinical relevance.

Weighted gene co-expression network analysis The present study sought to discover the easily tested new biomarker in multiple myeloma. The receiver operating characteristic curve determined key genes in Then, the diagnostic value of key genes was determined by the receiver operating characteristic curve. After the merger of WGCNA and DEGs, 238 key genes were screened. In addition, SNORNA is rarely studied in multiple myeloma, and our prediction model's ROC curve analysis showed that SNORA71A had a good prediction effect. SNORA71A was upregulated in 51 patient specimens compared to the healthy group, according to RT-PCR findings. Creinine was positively linked to SNORA71A, according to a linear correlation study. SNORA71A was up-regulated and associated with multiple myeloma's clinical stages, according to the study, and it indicates that SNORA71A may have been used as a novel biomarker for early diagnosis and a potential therapeutic target in multiple myeloma.

Source link: https://europepmc.org/article/MED/35231203


Comprehensive bioinformatics analysis reveals the hub genes and pathways associated with multiple myeloma.

Purpose: While the prognosis of multiple myeloma has risen over the last decade as a result of new treatment options, it is still incurable. MM microarray datasets related to MM were downloaded from the Gene Expression Omnibus database, which was downloaded from the Gene Expression Omnibus database. The hub genes were derived from the combined results of a protein-protein association network and weighted gene coexpression network analysis. To determine their clinical diagnostic value, the receiver operating characteristic curves of hub genes were plotted. Gene set enrichment analysis outlined biological pathways and signaling pathways associated with hub genes. The hub genes were also involved in the N-glycan biosynthesis pathway, according to the GSEA results. Conclusions: The hub genes identified in this study may partially explain the MM's potential molecular mechanisms and serve as candidate biomarkers for disease diagnosis and disease prevention.

Source link: https://europepmc.org/article/MED/35192775


Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.

In transplant-eligible newly diagnosed multiple myeloma patients in Japan, we conducted a phase II trial to objectively establish the effectiveness and safety of bortezomib-cyclophosphamide-dexamethasone induction, autologous stem cell transplantation, VCD reconstruction, and bortezomib maintenance. Methods From 2013 to 2016, 42 patients with a median age of 58 years with NDMM were accepted in 15 centers. Results Following induction therapy, the overall response rate was achieved in 71% of patients, with a CR/sCR of 10% and a good partial response of 26%. Following the protocol and CR/sCR and VGPR rates 100 days after ASCT was 26% and 17%, respectively, twenty-six of the 42 patients completed ASCT. Without disease progression and grade 3/4 toxicities, eight of the 18 patients underwent 2-year bortezomib therapy. After ASCT, Five patients were VGPR or partial response, but the patient's response was consistent with 2-year bortezomib maintenance.

Source link: https://europepmc.org/article/MED/35152852


Pomalidomide-based therapy for extramedullary multiple myeloma.

In multiple myeloma patients, plasma cells outside of bone marrow are characterized, resulting in an adverse prognosis. Only limited data is available on pomalidomide-based therapy for EMD patients. The aim of the current research was to determine the toxicity of pomalidomide-based therapy in EMD. Methods Six patients' new retrospective review evaluated the effectiveness of pomalidomide-based therapy in the treatment of EMD. With 50% CR, 33% PR, and extraullary progression in one patient, the average response rate in an extra patient was 83%. Pomalidomide-based therapy demonstrated success in these previously treated patients with EMD, according to the review and conclusion.

Source link: https://europepmc.org/article/MED/35068387


The effect of marital status on the survival of patients with multiple myeloma.

We compared overall survival and cancer-specific survival differences by the Kaplan-Meier technique and log-rank tests. By Cox regression estimates, the hazard ratios for OS and CSS were estimated with 95% confidence intervals. To minimize covariates differences between married and unmarried couples, a 1:1 propensity score matching study was used. Results This report identified 48,952 eligible patients with MM, including 29,607 married patients, 5,147 divorced/separated patients, 6,851 single patients, and 7,347 widowed patients. Married MM patients were found to be an independent protective prognostic factor for OS and CSS. According to the stratified review, the OS and CSS were poorer in single married than married MM patients of various age, sex, wealth, ethnicity, and time of diagnosis subgroups. Conclusion Married patients with MM have more OS and CSS likely because of their higher income, education level, insurance, and receipt of chemotherapy.

Source link: https://europepmc.org/article/MED/35068385


Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis.

The prognosis of multiple myeloma patients has been shown by several research, but the prognostic significance remains uncertain. The results indicated that CD56 negativity in MM was related to poorer OS and PFS. According to Subgroup study, treatment regimen, sampling method, survival analysis, population control, study area, and the cut-off value of CD56 expression was among the effects of treatment regimen, diagnosis method, survival estimation, study area, and the cut-off value of CD56 expression. Discussion and conclusion The meta-analysis revealed that CD56 negative patients had a poor prognosis for OS in Asian patients and PFS in non-Asian patients.

Source link: https://europepmc.org/article/MED/35068378


miR-140-3p attenuated the tumorigenesis of multiple myeloma via attenuating BZW2.

Physiology Among B-cell lymphoma, multiple myeloma is an incurable disease. However, the role of miR-140-3p in MM remains unclear. The western blot determined the protein content of BZW2 by the western blot. MiR-140-3p overpreciation increased the proliferation of MM cell lines and triggered apoptosis in MM cells. BZW2 was instrumental in the establishment of miR-140-3p on MM cell vitality and apoptosis. MiR-140-3p blocked tumor formation of MM cell lines in nude mice, according to an In vivo study. Conclusion of the present study MiR-140-3p served as a stifle in MM by negatively controlling BZW2.

Source link: https://europepmc.org/article/MED/35068373

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions